Načítá se...
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma
Pembrolizumab is an effective therapy in patients with metastatic melanoma. However, not all patients derive benefit. It is postulated that an increase in regulatory T cells in melanoma patients can impair the response to immunotherapies. Continuous low dose temozolomide has shown to cause immunomod...
Uloženo v:
| Vydáno v: | Melanoma Res |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717692/ https://ncbi.nlm.nih.gov/pubmed/30829928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000592 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|